ArticleStem cell research & therapy2025
Systematic evaluation of porcine platelet lysate as a fetal bovine serum substitute: enhancing cell proliferation, maintaining differentiation potential, and ensuring immunophenotypic stability.
Article in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Plasma-Depleted Lyophilized Porcine Platelet Lysate as an Alternative to Fetal Bovine Serum in Cell Culture.Life (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThis study systematically evaluated the potential of porcine platelet-lysate (pPL) as a fetal bovine serum (FBS) substitute in cell culture. By culturing tumor cells, adult cells, and stem cells, it analyzed the differences and advantages of pPL over FBS.
methodspPL was prepared using the freeze - thaw method. Its biological effects were assessed by cell counting, LDH cytotoxicity assays, flow cytometry, and adipogenic/osteogenic/chondrogenic differentiation experiments, combined with qPCR and histological staining.
resultspPL significantly promoted the proliferation of A375 and HDF cells, with much lower LDH release than the FBS group, indicating less cellular stress. Flow cytometry showed that MSCs in the pPL group stably expressed mesenchymal markers CD73 ⁺ /CD90 ⁺ (>95%) and had lowCD34 ⁻ (＜2％), meeting ISCT standards. Differentiation experiments revealed that the pPL group had better osteogenic differentiation efficiency, similar chondrogenic ability, and slightly lower but normal adipogenic differentiation compared to the FBS group.
conclusionspPL effectively supports the in vitro expansion of various cells, helps maintain the immunophenotypic stability of MSCs, and shows superiority in osteogenic differentiation. With its unique "proliferation-first, differentiation-controllable" advantage from a natural growth factor network, pPL offers a new approach for developing FBS substitutes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.